Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
63 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Neisseria Gonorrhoeae Infections - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Neisseria Gonorrhoeae Infections - Pipeline Review, H2 2014', provides an overview of the Neisseria Gonorrhoeae Infections's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neisseria Gonorrhoeae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neisseria Gonorrhoeae Infections and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Neisseria Gonorrhoeae Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neisseria Gonorrhoeae Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neisseria Gonorrhoeae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neisseria Gonorrhoeae Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Neisseria Gonorrhoeae Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Neisseria Gonorrhoeae Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Neisseria Gonorrhoeae Infections Overview 7 Therapeutics Development 8 Pipeline Products for Neisseria Gonorrhoeae Infections - Overview 8 Pipeline Products for Neisseria Gonorrhoeae Infections - Comparative Analysis 9 Neisseria Gonorrhoeae Infections - Therapeutics under Development by Companies 10 Neisseria Gonorrhoeae Infections - Therapeutics under Investigation by Universities/Institutes 11 Neisseria Gonorrhoeae Infections - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Neisseria Gonorrhoeae Infections - Products under Development by Companies 14 Neisseria Gonorrhoeae Infections - Products under Investigation by Universities/Institutes 15 Neisseria Gonorrhoeae Infections - Companies Involved in Therapeutics Development 16 Adenium Biotech ApS 16 AstraZeneca PLC 17 BioDiem Ltd 18 Biolytics Pharma 19 Debiopharm International S.A. 20 Durata Therapeutics, Inc. 21 Sumitomo Dainippon Pharma Co., Ltd. 22 Vertex Pharmaceuticals Incorporated 23 Neisseria Gonorrhoeae Infections - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Target 25 Assessment by Mechanism of Action 27 Assessment by Route of Administration 29 Assessment by Molecule Type 31 Drug Profiles 33 Arenicin - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 AZD-0914 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 BDM-I - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Biologic for Neisseria Gonorrhoeae Infection - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Cribrostatin-6 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 dalbavancin - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Debio-1453 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 gonorrhoeae vaccine - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 SM-295291 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 SM-369926 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Small Molecule to Inhibit Tubulin for Neuroblastoma and Neisseria Gonorrhoeae Infections - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Vaccine for Neisseria Gonorrhoeae Infection - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 VT-12008911 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Neisseria Gonorrhoeae Infections - Recent Pipeline Updates 48 Neisseria Gonorrhoeae Infections - Dormant Projects 57 Neisseria Gonorrhoeae Infections - Product Development Milestones 58 Featured News & Press Releases 58 Sep 09, 2014: Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 58 Jun 03, 2014: AstraZeneca's novel antibiotic candidate AZD0914 given Fast Track status by US FDA 60 Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I 60 Appendix 62 Methodology 62 Coverage 62 Secondary Research 62 Primary Research 62 Expert Panel Validation 62 Contact Us 63 Disclaimer 63
List of Tables Number of Products under Development for Neisseria Gonorrhoeae Infections, H2 2014 8 Number of Products under Development for Neisseria Gonorrhoeae Infections - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Products under Development by Companies, H2 2014 14 Products under Investigation by Universities/Institutes, H2 2014 15 Neisseria Gonorrhoeae Infections - Pipeline by Adenium Biotech ApS, H2 2014 16 Neisseria Gonorrhoeae Infections - Pipeline by AstraZeneca PLC, H2 2014 17 Neisseria Gonorrhoeae Infections - Pipeline by BioDiem Ltd, H2 2014 18 Neisseria Gonorrhoeae Infections - Pipeline by Biolytics Pharma, H2 2014 19 Neisseria Gonorrhoeae Infections - Pipeline by Debiopharm International S.A., H2 2014 20 Neisseria Gonorrhoeae Infections - Pipeline by Durata Therapeutics, Inc., H2 2014 21 Neisseria Gonorrhoeae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 22 Neisseria Gonorrhoeae Infections - Pipeline by Vertex Pharmaceuticals Incorporated, H2 2014 23 Assessment by Monotherapy Products, H2 2014 24 Number of Products by Stage and Target, H2 2014 26 Number of Products by Stage and Mechanism of Action, H2 2014 28 Number of Products by Stage and Route of Administration, H2 2014 30 Number of Products by Stage and Molecule Type, H2 2014 32 Neisseria Gonorrhoeae Infections Therapeutics - Recent Pipeline Updates, H2 2014 48 Neisseria Gonorrhoeae Infections - Dormant Projects, H2 2014 57
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
